APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Vaccine for Human

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oral Vaccine for Human Industry Growth and Trends Forecast to 2032

29 December 2025110 pages

Choose your research edition.

Industry ResearchOral Vaccine for Human Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Vaccine for Human Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oral Vaccine for Human Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Vaccine for Human Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Vaccine for Human Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Oral Vaccine for Human market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Vaccine for Human include Bibcol, Bio-Med, EuBiologics, Halfkin Bio-Pharmaceuticals, Panacea Biotec Ltd, PaxVax, Serum Institute, Vabiotech and Valneva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oral Vaccine for Human market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oral Vaccine for Human market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oral Vaccine for Human market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oral Vaccine for Human.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Oral Vaccine for Human market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oral Vaccine for Human Market by Company

Bibcol

Bio-Med

EuBiologics

Halfkin Bio-Pharmaceuticals

Panacea Biotec Ltd

PaxVax

Serum Institute

Vabiotech

Valneva

Tiantan Biological

GSK

Merck

Sanofi

Shanghai United Cell

Lanzhou Institute

Oral Vaccine for Human Segment by Type

Cholera Vaccine

Oral Polio Vaccine

Rotavirus Vaccine

Other

Oral Vaccine for Human Segment by Application

Public

Private

Oral Vaccine for Human Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Vaccine for Human market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Vaccine for Human and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Vaccine for Human.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Vaccine for Human manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Oral Vaccine for Human in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Cholera Vaccine Table 2. Major Company of Oral Polio Vaccine Table 3. Major Company of Rotavirus Vaccine Table 4. Major Company of Other Table 5. Global Oral Vaccine for Human Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 7. Global Oral Vaccine for Human Sales Market Share in Volume by Type (2021-2026) Table 8. Global Oral Vaccine for Human Sales by Type (2021-2026) & (US$ Million) Table 9. Global Oral Vaccine for Human Sales Market Share in Value by Type (2021-2026) Table 10. Global Oral Vaccine for Human Price by Type (2021-2026) & (US$/Unit) Table 11. Global Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 12. Global Oral Vaccine for Human Sales Market Share in Volume by Type (2027-2032) Table 13. Global Oral Vaccine for Human Sales by Type (2027-2032) & (US$ Million) Table 14. Global Oral Vaccine for Human Sales Market Share in Value by Type (2027-2032) Table 15. Global Oral Vaccine for Human Price by Type (2027-2032) & (US$/Unit) Table 16. North America Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 17. North America Oral Vaccine for Human Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 19. Europe Oral Vaccine for Human Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Oral Vaccine for Human Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 23. Latin America Oral Vaccine for Human Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Oral Vaccine for Human Sales by Type (2021-2026) & (US$ Million) Table 26. Oral Vaccine for Human Industry Trends Table 27. Oral Vaccine for Human Industry Drivers Table 28. Oral Vaccine for Human Industry Opportunities and Challenges Table 29. Oral Vaccine for Human Industry Restraints Table 30. Global Oral Vaccine for Human Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Oral Vaccine for Human Revenue Market Share by Company (2021-2026) Table 32. Global Oral Vaccine for Human Sales by Company (2021-2026) & (K Units) Table 33. Global Oral Vaccine for Human Sales Share by Company (2021-2026) Table 34. Global Oral Vaccine for Human Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Oral Vaccine for Human Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Oral Vaccine for Human Major Company Production Sites and Headquarters Table 37. Global Oral Vaccine for Human Company, Product Type & Application Table 38. Global Oral Vaccine for Human Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Oral Vaccine for Human by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Oral Vaccine for Human Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Oral Vaccine for Human Sales by Region (2021-2026) & (K Units) Table 43. Global Oral Vaccine for Human Sales Market Share in Volume by Region (2021-2026) Table 44. Global Oral Vaccine for Human Sales by Region (2021-2026) & (US$ Million) Table 45. Global Oral Vaccine for Human Sales Market Share in Value by Region (2021-2026) Table 46. Global Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Oral Vaccine for Human Sales by Region (2027-2032) & (K Units) Table 48. Global Oral Vaccine for Human Sales Market Share in Volume by Region (2027-2032) Table 49. Global Oral Vaccine for Human Sales by Region (2027-2032) & (US$ Million) Table 50. Global Oral Vaccine for Human Sales Market Share in Value by Region (2027-2032) Table 51. Global Oral Vaccine for Human Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Oral Vaccine for Human Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 54. Global Oral Vaccine for Human Sales Market Share in Volume by Application (2021-2026) Table 55. Global Oral Vaccine for Human Sales by Application (2021-2026) & (US$ Million) Table 56. Global Oral Vaccine for Human Sales Market Share in Value by Application (2021-2026) Table 57. Global Oral Vaccine for Human Price by Application (2021-2026) & (US$/Unit) Table 58. Global Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 59. Global Oral Vaccine for Human Sales Market Share in Volume by Application (2027-2032) Table 60. Global Oral Vaccine for Human Sales by Application (2027-2032) & (US$ Million) Table 61. Global Oral Vaccine for Human Sales Market Share in Value by Application (2027-2032) Table 62. Global Oral Vaccine for Human Price by Application (2027-2032) & (US$/Unit) Table 63. North America Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 64. North America Oral Vaccine for Human Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 66. Europe Oral Vaccine for Human Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Oral Vaccine for Human Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 70. Latin America Oral Vaccine for Human Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Oral Vaccine for Human Sales by Application (2021-2026) & (US$ Million) Table 73. Bibcol Company Information Table 74. Bibcol Business Overview Table 75. Bibcol Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bibcol Oral Vaccine for Human Product Portfolio Table 77. Bibcol Recent Development Table 78. Bio-Med Company Information Table 79. Bio-Med Business Overview Table 80. Bio-Med Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Bio-Med Oral Vaccine for Human Product Portfolio Table 82. Bio-Med Recent Development Table 83. EuBiologics Company Information Table 84. EuBiologics Business Overview Table 85. EuBiologics Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. EuBiologics Oral Vaccine for Human Product Portfolio Table 87. EuBiologics Recent Development Table 88. Halfkin Bio-Pharmaceuticals Company Information Table 89. Halfkin Bio-Pharmaceuticals Business Overview Table 90. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio Table 92. Halfkin Bio-Pharmaceuticals Recent Development Table 93. Panacea Biotec Ltd Company Information Table 94. Panacea Biotec Ltd Business Overview Table 95. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio Table 97. Panacea Biotec Ltd Recent Development Table 98. PaxVax Company Information Table 99. PaxVax Business Overview Table 100. PaxVax Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. PaxVax Oral Vaccine for Human Product Portfolio Table 102. PaxVax Recent Development Table 103. Serum Institute Company Information Table 104. Serum Institute Business Overview Table 105. Serum Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Serum Institute Oral Vaccine for Human Product Portfolio Table 107. Serum Institute Recent Development Table 108. Vabiotech Company Information Table 109. Vabiotech Business Overview Table 110. Vabiotech Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Vabiotech Oral Vaccine for Human Product Portfolio Table 112. Vabiotech Recent Development Table 113. Valneva Company Information Table 114. Valneva Business Overview Table 115. Valneva Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Valneva Oral Vaccine for Human Product Portfolio Table 117. Valneva Recent Development Table 118. Tiantan Biological Company Information Table 119. Tiantan Biological Business Overview Table 120. Tiantan Biological Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Tiantan Biological Oral Vaccine for Human Product Portfolio Table 122. Tiantan Biological Recent Development Table 123. GSK Company Information Table 124. GSK Business Overview Table 125. GSK Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. GSK Oral Vaccine for Human Product Portfolio Table 127. GSK Recent Development Table 128. Merck Company Information Table 129. Merck Business Overview Table 130. Merck Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Merck Oral Vaccine for Human Product Portfolio Table 132. Merck Recent Development Table 133. Sanofi Company Information Table 134. Sanofi Business Overview Table 135. Sanofi Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Sanofi Oral Vaccine for Human Product Portfolio Table 137. Sanofi Recent Development Table 138. Shanghai United Cell Company Information Table 139. Shanghai United Cell Business Overview Table 140. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Shanghai United Cell Oral Vaccine for Human Product Portfolio Table 142. Shanghai United Cell Recent Development Table 143. Lanzhou Institute Company Information Table 144. Lanzhou Institute Business Overview Table 145. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Lanzhou Institute Oral Vaccine for Human Product Portfolio Table 147. Lanzhou Institute Recent Development Table 148. North America Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 149. North America Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 150. North America Oral Vaccine for Human Sales Market Share by Country (2021-2026) Table 151. North America Oral Vaccine for Human Sales Forecast by Country (2027-2032) & (K Units) Table 152. North America Oral Vaccine for Human Sales Market Share Forecast by Country (2027-2032) Table 153. North America Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Oral Vaccine for Human Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Oral Vaccine for Human Market Share by Country (2021-2026) Table 156. North America Oral Vaccine for Human Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Oral Vaccine for Human Market Share Forecast by Country (2027-2032) Table 158. Europe Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 159. Europe Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 160. Europe Oral Vaccine for Human Sales Market Share by Country (2021-2026) Table 161. Europe Oral Vaccine for Human Sales Forecast by Country (2027-2032) & (K Units) Table 162. Europe Oral Vaccine for Human Sales Market Share Forecast by Country (2027-2032) Table 163. Europe Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe Oral Vaccine for Human Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe Oral Vaccine for Human Market Share by Country (2021-2026) Table 166. Europe Oral Vaccine for Human Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe Oral Vaccine for Human Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 170. Asia-Pacific Oral Vaccine for Human Sales Market Share by Country (2021-2026) Table 171. Asia-Pacific Oral Vaccine for Human Sales Forecast by Country (2027-2032) & (K Units) Table 172. Asia-Pacific Oral Vaccine for Human Sales Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Oral Vaccine for Human Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific Oral Vaccine for Human Market Share by Country (2021-2026) Table 176. Asia-Pacific Oral Vaccine for Human Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific Oral Vaccine for Human Market Share Forecast by Country (2027-2032) Table 178. Latin America Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 179. Latin America Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 180. Latin America Oral Vaccine for Human Sales Market Share by Country (2021-2026) Table 181. Latin America Oral Vaccine for Human Sales Forecast by Country (2027-2032) & (K Units) Table 182. Latin America Oral Vaccine for Human Sales Market Share Forecast by Country (2027-2032) Table 183. Latin America Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Latin America Oral Vaccine for Human Market Size by Country (2021-2026) & (US$ Million) Table 185. Latin America Oral Vaccine for Human Market Share by Country (2021-2026) Table 186. Latin America Oral Vaccine for Human Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Latin America Oral Vaccine for Human Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 190. Middle East and Africa Oral Vaccine for Human Sales Market Share by Country (2021-2026) Table 191. Middle East and Africa Oral Vaccine for Human Sales Forecast by Country (2027-2032) & (K Units) Table 192. Middle East and Africa Oral Vaccine for Human Sales Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Oral Vaccine for Human Market Size by Country (2021-2026) & (US$ Million) Table 195. Middle East and Africa Oral Vaccine for Human Market Share by Country (2021-2026) Table 196. Middle East and Africa Oral Vaccine for Human Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Oral Vaccine for Human Market Share Forecast by Country (2027-2032) Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. Oral Vaccine for Human Distributors List Table 201. Oral Vaccine for Human Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Oral Vaccine for Human Image Figure 2. Global Oral Vaccine for Human Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Vaccine for Human Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Vaccine for Human Sales (2021-2032) & (K Units) Figure 5. Cholera Vaccine Image Figure 6. Global Cholera Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Oral Polio Vaccine Image Figure 8. Global Oral Polio Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Rotavirus Vaccine Image Figure 10. Global Rotavirus Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Oral Vaccine for Human Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Oral Vaccine for Human Market Share by Type 2025 VS 2032 Figure 15. North America Oral Vaccine for Human Sales Market Share in Volume by Type in 2025 Figure 16. North America Oral Vaccine for Human Sales Market Share in Value by Type in 2025 Figure 17. Europe Oral Vaccine for Human Sales Market Share in Volume by Type in 2025 Figure 18. Europe Oral Vaccine for Human Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Oral Vaccine for Human Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Oral Vaccine for Human Sales Market Share in Value by Type in 2025 Figure 21. Latin America Oral Vaccine for Human Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Oral Vaccine for Human Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Oral Vaccine for Human Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Oral Vaccine for Human Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Oral Vaccine for Human Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Public Image Figure 28. Global Public Sales YoY Growth (2021-2032) & (K Units) Figure 29. Private Image Figure 30. Global Private Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Oral Vaccine for Human Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Oral Vaccine for Human Market Share by Application 2025 VS 2032 Figure 33. North America Oral Vaccine for Human Sales Market Share in Volume by Application in 2025 Figure 34. North America Oral Vaccine for Human Sales Market Share in Value by Application in 2025 Figure 35. Europe Oral Vaccine for Human Sales Market Share in Volume by Application in 2025 Figure 36. Europe Oral Vaccine for Human Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Oral Vaccine for Human Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Oral Vaccine for Human Sales Market Share in Value by Application in 2025 Figure 39. Latin America Oral Vaccine for Human Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Oral Vaccine for Human Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Oral Vaccine for Human Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Oral Vaccine for Human Sales Market Share in Value by Application in 2025 Figure 43. North America Oral Vaccine for Human Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Oral Vaccine for Human Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Oral Vaccine for Human Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Oral Vaccine for Human Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Oral Vaccine for Human Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Oral Vaccine for Human Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Oral Vaccine for Human Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Oral Vaccine for Human Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Oral Vaccine for Human Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Oral Vaccine for Human Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Oral Vaccine for Human Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Oral Vaccine for Human Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Oral Vaccine for Human Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Oral Vaccine for Human Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Oral Vaccine for Human Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Oral Vaccine for Human Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Oral Vaccine for Human Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Oral Vaccine for Human Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Cholera Vaccine
  • Oral Polio Vaccine
  • Rotavirus Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Bibcol
  • Bio-Med
  • EuBiologics
  • Halfkin Bio-Pharmaceuticals
  • Panacea Biotec Ltd
  • PaxVax
  • Serum Institute
  • Vabiotech
  • Valneva
  • Tiantan Biological
  • GSK
  • Merck
  • Sanofi
  • Shanghai United Cell
  • Lanzhou Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Vaccine for Human Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Oral Vaccine for Human Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Oral Vaccine for Human Market by Type
  6. 1.3.1 Cholera Vaccine
  7. 1.3.2 Oral Polio Vaccine
  8. 1.3.3 Rotavirus Vaccine
  9. 1.3.4 Other
  10. 1.4 Global Oral Vaccine for Human Market Size by Type
  11. 1.4.1 Global Oral Vaccine for Human Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Oral Vaccine for Human Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Oral Vaccine for Human Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Oral Vaccine for Human Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Oral Vaccine for Human Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Oral Vaccine for Human Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Oral Vaccine for Human Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Oral Vaccine for Human Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Oral Vaccine for Human Industry Trends
  2. 2.2 Oral Vaccine for Human Industry Drivers
  3. 2.3 Oral Vaccine for Human Industry Opportunities and Challenges
  4. 2.4 Oral Vaccine for Human Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Oral Vaccine for Human Revenue (2021-2026)
  2. 3.2 Global Top Players by Oral Vaccine for Human Sales (2021-2026)
  3. 3.3 Global Top Players by Oral Vaccine for Human Price (2021-2026)
  4. 3.4 Global Oral Vaccine for Human Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Vaccine for Human Major Company Production Sites & Headquarters
  6. 3.6 Global Oral Vaccine for Human Company, Product Type & Application
  7. 3.7 Global Oral Vaccine for Human Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Vaccine for Human Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Vaccine for Human Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Vaccine for Human Tier 1, Tier 2, and Tier 3
4 Oral Vaccine for Human Regional Status and Outlook
  1. 4.1 Global Oral Vaccine for Human Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Oral Vaccine for Human Historic Market Size by Region
  3. 4.2.1 Global Oral Vaccine for Human Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Oral Vaccine for Human Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Oral Vaccine for Human Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Oral Vaccine for Human Forecasted Market Size by Region
  7. 4.3.1 Global Oral Vaccine for Human Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Oral Vaccine for Human Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Oral Vaccine for Human Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Oral Vaccine for Human by Application
  1. 5.1 Oral Vaccine for Human Market by Application
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Oral Vaccine for Human Market Size by Application
  5. 5.2.1 Global Oral Vaccine for Human Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Oral Vaccine for Human Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Oral Vaccine for Human Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Oral Vaccine for Human Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Oral Vaccine for Human Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Oral Vaccine for Human Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Oral Vaccine for Human Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Oral Vaccine for Human Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bibcol
  2. 6.1.1 Bibcol Company Information
  3. 6.1.2 Bibcol Business Overview
  4. 6.1.3 Bibcol Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bibcol Oral Vaccine for Human Product Portfolio
  6. 6.1.5 Bibcol Recent Developments
  7. 6.2 Bio-Med
  8. 6.2.1 Bio-Med Company Information
  9. 6.2.2 Bio-Med Business Overview
  10. 6.2.3 Bio-Med Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bio-Med Oral Vaccine for Human Product Portfolio
  12. 6.2.5 Bio-Med Recent Developments
  13. 6.3 EuBiologics
  14. 6.3.1 EuBiologics Company Information
  15. 6.3.2 EuBiologics Business Overview
  16. 6.3.3 EuBiologics Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 EuBiologics Oral Vaccine for Human Product Portfolio
  18. 6.3.5 EuBiologics Recent Developments
  19. 6.4 Halfkin Bio-Pharmaceuticals
  20. 6.4.1 Halfkin Bio-Pharmaceuticals Company Information
  21. 6.4.2 Halfkin Bio-Pharmaceuticals Business Overview
  22. 6.4.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
  24. 6.4.5 Halfkin Bio-Pharmaceuticals Recent Developments
  25. 6.5 Panacea Biotec Ltd
  26. 6.5.1 Panacea Biotec Ltd Company Information
  27. 6.5.2 Panacea Biotec Ltd Business Overview
  28. 6.5.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
  30. 6.5.5 Panacea Biotec Ltd Recent Developments
  31. 6.6 PaxVax
  32. 6.6.1 PaxVax Company Information
  33. 6.6.2 PaxVax Business Overview
  34. 6.6.3 PaxVax Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 PaxVax Oral Vaccine for Human Product Portfolio
  36. 6.6.5 PaxVax Recent Developments
  37. 6.7 Serum Institute
  38. 6.7.1 Serum Institute Company Information
  39. 6.7.2 Serum Institute Business Overview
  40. 6.7.3 Serum Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Serum Institute Oral Vaccine for Human Product Portfolio
  42. 6.7.5 Serum Institute Recent Developments
  43. 6.8 Vabiotech
  44. 6.8.1 Vabiotech Company Information
  45. 6.8.2 Vabiotech Business Overview
  46. 6.8.3 Vabiotech Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Vabiotech Oral Vaccine for Human Product Portfolio
  48. 6.8.5 Vabiotech Recent Developments
  49. 6.9 Valneva
  50. 6.9.1 Valneva Company Information
  51. 6.9.2 Valneva Business Overview
  52. 6.9.3 Valneva Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Valneva Oral Vaccine for Human Product Portfolio
  54. 6.9.5 Valneva Recent Developments
  55. 6.10 Tiantan Biological
  56. 6.10.1 Tiantan Biological Company Information
  57. 6.10.2 Tiantan Biological Business Overview
  58. 6.10.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
  60. 6.10.5 Tiantan Biological Recent Developments
  61. 6.11 GSK
  62. 6.11.1 GSK Company Information
  63. 6.11.2 GSK Business Overview
  64. 6.11.3 GSK Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 GSK Oral Vaccine for Human Product Portfolio
  66. 6.11.5 GSK Recent Developments
  67. 6.12 Merck
  68. 6.12.1 Merck Company Information
  69. 6.12.2 Merck Business Overview
  70. 6.12.3 Merck Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Merck Oral Vaccine for Human Product Portfolio
  72. 6.12.5 Merck Recent Developments
  73. 6.13 Sanofi
  74. 6.13.1 Sanofi Company Information
  75. 6.13.2 Sanofi Business Overview
  76. 6.13.3 Sanofi Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Sanofi Oral Vaccine for Human Product Portfolio
  78. 6.13.5 Sanofi Recent Developments
  79. 6.14 Shanghai United Cell
  80. 6.14.1 Shanghai United Cell Company Information
  81. 6.14.2 Shanghai United Cell Business Overview
  82. 6.14.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
  84. 6.14.5 Shanghai United Cell Recent Developments
  85. 6.15 Lanzhou Institute
  86. 6.15.1 Lanzhou Institute Company Information
  87. 6.15.2 Lanzhou Institute Business Overview
  88. 6.15.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
  90. 6.15.5 Lanzhou Institute Recent Developments
7 North America by Country
  1. 7.1 North America Oral Vaccine for Human Sales by Country
  2. 7.1.1 North America Oral Vaccine for Human Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Oral Vaccine for Human Sales by Country (2021-2026)
  4. 7.1.3 North America Oral Vaccine for Human Sales Forecast by Country (2027-2032)
  5. 7.2 North America Oral Vaccine for Human Market Size by Country
  6. 7.2.1 North America Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Oral Vaccine for Human Market Size by Country (2021-2026)
  8. 7.2.3 North America Oral Vaccine for Human Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Oral Vaccine for Human Sales by Country
  2. 8.1.1 Europe Oral Vaccine for Human Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Oral Vaccine for Human Sales by Country (2021-2026)
  4. 8.1.3 Europe Oral Vaccine for Human Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Oral Vaccine for Human Market Size by Country
  6. 8.2.1 Europe Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Oral Vaccine for Human Market Size by Country (2021-2026)
  8. 8.2.3 Europe Oral Vaccine for Human Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Oral Vaccine for Human Sales by Country
  2. 9.1.1 Asia-Pacific Oral Vaccine for Human Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Oral Vaccine for Human Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Oral Vaccine for Human Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Oral Vaccine for Human Market Size by Country
  6. 9.2.1 Asia-Pacific Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Oral Vaccine for Human Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Oral Vaccine for Human Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Oral Vaccine for Human Sales by Country
  2. 10.1.1 South America Oral Vaccine for Human Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Oral Vaccine for Human Sales by Country (2021-2026)
  4. 10.1.3 South America Oral Vaccine for Human Sales Forecast by Country (2027-2032)
  5. 10.2 South America Oral Vaccine for Human Market Size by Country
  6. 10.2.1 South America Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Oral Vaccine for Human Market Size by Country (2021-2026)
  8. 10.2.3 South America Oral Vaccine for Human Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Oral Vaccine for Human Sales by Country
  2. 11.1.1 Middle East and Africa Oral Vaccine for Human Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Oral Vaccine for Human Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Oral Vaccine for Human Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Oral Vaccine for Human Market Size by Country
  6. 11.2.1 Middle East and Africa Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Oral Vaccine for Human Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Oral Vaccine for Human Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Oral Vaccine for Human Value Chain Analysis
  2. 12.1.1 Oral Vaccine for Human Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Oral Vaccine for Human Production Mode & Process
  7. 12.2 Oral Vaccine for Human Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Oral Vaccine for Human Distributors
  10. 12.2.3 Oral Vaccine for Human Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst